Document is current

Article History

Received: 20 April 2024

Accepted: 11 October 2024

First Online: 11 November 2024

Declarations

:

: The study was approved by the Institutional Ethical Review Boards (AD CSF biobank METC number.00–211) and informed consent was obtained from all subjects or their authorized representatives.

: Not applicable.

: MC has been an invited speaker at Eisai and Novonordisk. She is an associate editor at Alzheimer´s Research & Therapy and has been an invited writer for Springer Healthcare. LV received a grant for CORAL consortium by Olink, and has been invited speaker for Eli Lilly, and consultant for Roche. IV received a TKI Health ~ Holland grant for a collaborative project with OLINK and Quanterix. IV has been an invited speaker by Quanterix, funding is paid to her institution. WvF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. WF is member of steering cie of NovoNordisk evoke/evoke + . WvF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. WvF is member of the steering committee of PAVE, and Think Brain Health. WvF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WvF is associate editor at Brain. CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, Novo Nordisk. The rest of the authors declare no competing interest.